News > GSK Antibody Treatment Works on Omicron Mutations, Study Shows

GSK Antibody Treatment Works on Omicron Mutations, Study Shows

GlaxoSmithKline Plc said research shows its Covid-19 antibody treatment is effective against the full combination of mutations in the new omicron variant.

Sotrovimab, Glaxo’s antibody treatment, stands up to all mutations in the spike protein of the omicron variant and not just the key mutations, the drugmaker said. The tests included all 37 mutations identified to date in the spike protein.